- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06355804
Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis
The overall objective of the current study is to determine the efficacy of a 16-week remotely delivered lifestyle behavioral intervention compared with a control condition (i.e., waitlist control) in persons newly diagnosed with MS (disease duration ≤ 2 years).
Specific Aim 1: To evaluate the changes in self-report and device-measured physical activity after the 16-week remotely delivered physical activity behavior change intervention compared with a control condition (i.e., waitlist control) in persons who have diagnosed with MS within the past two years. The investigators hypothesize that the 16-week behavior change intervention will yield greater improvements in physical activity levels than the control condition immediately after the intervention.
Specific Aim 2: To investigate the efficacy of the 16-week, remotely delivered physical activity behavior change intervention compared with the control condition for improvements in fatigue, depression, anxiety, and QoL in persons newly diagnosed with MS. The investigators hypothesize that there will be beneficial effects on the symptoms and QoL outcomes immediately after the physical activity intervention compared with minimal changes in the control condition.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Chicago
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged 18 years or older
- self-reported diagnosis of MS by a neurologist within the past 2 years
- relapse-free for the past 30 days
- ability to speak and read English as primary language
- internet and e-mail access, and willingness to complete the testing and questionnaires
- ambulatory without an assistive device (e.g., cane)
- insufficiently active (Godin Leisure-Time Exercise Questionnaire (GLTEQ) < 14)
- visual ability and literacy to read newsletter with font size 14 points
- on a disease-modifying therapy.
Exclusion Criteria:
- pregnant
- have elevated risk for undertaking strenuous or maximal exercise based on two or more affirmatives on the Physical Activity Readiness Questionnaire (PAR-Q)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Physical activity condition
Participants in this arm will receive a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular one-on-one coaching chats (15 - 30 minutes) over Zoom with a behavioral coach after the baseline assessment.
Throughout the 16-week period, The investigators will ask participants to wear a Fitbit (provided) for tracking daily physical activity.
|
Participants will receive a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:
|
|
Other: Waitlist condition
Participants will receive access to a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular one-on-one coaching chats (15-30 minutes) over Zoom with a behavioral coach after the follow-up assessment.
|
Participants will receive access to a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical Activity Behavior
Time Frame: Changes in the GLTEQ scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Godin Leisure-Time Exercise Questionnaire (GLTEQ); scores range between 0 (min) and 119 (max), higher scores indicate greater engagement in physical activity behavior.
|
Changes in the GLTEQ scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Physical Activity Behavior
Time Frame: Changes in the IPAQ scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
International Physical Activity Questionnaire (IPAQ); scores range between 0 (min) and 107 (max), higher scores indicate greater engagement in physical activity behavior.
|
Changes in the IPAQ scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Physical Activity Level (Light physical activity)
Time Frame: Changes in time spent in LPA from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Time (minutes/day) spent in light physical activity (LPA) will be measured by a waist-worn accelerometer (ActiGraph model GT3X+); participants will wear the accelerometer on a belt around their waist during the waking hours of a 7 day period; a longer time of LPA reflects a higher level of physical activity.
|
Changes in time spent in LPA from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Physical Activity Level (Moderate-to-vigorous physical activity)
Time Frame: Changes in time spent in MVPA from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Time (minutes/day) spent in moderate-to-vigorous physical activity (MVPA) will be measured by a waist-worn accelerometer (ActiGraph model GT3X+); participants will wear the accelerometer on a belt around their waist during the waking hours of a 7 day period; a longer time of MVPA reflects a higher level of physical activity.
|
Changes in time spent in MVPA from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Physical Activity Level (Daily step count)
Time Frame: Changes in time spent in daily step count from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Daily step count will be measured by a waist-worn accelerometer (ActiGraph model GT3X+); participants will wear the accelerometer on a belt around their waist during the waking hours of a 7 day period; a greater number of steps per day reflects a higher level of physical activity.
|
Changes in time spent in daily step count from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health-related quality of Life
Time Frame: Changes in SF-12 scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Short Form Health Status Survey (SF-12); scores range between 0 (min) and 100 (max), higher scores indicate better physical and mental aspects of quality of life.
|
Changes in SF-12 scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Health-related Quality of Life
Time Frame: Changes in MSIS-29 scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Multiple Sclerosis Impact Scale (MSIS-29); scores range between 0 (min) and 100 (max), higher scores indicate greater impact of disease on daily function (i.e.
worse outcomes).
|
Changes in MSIS-29 scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Fatigue Severity
Time Frame: Changes in fatigue severity scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Fatigue Severity Scale (FSS); scores range between 1 (min) and 7 (max), higher scores reflect greater fatigue severity.
|
Changes in fatigue severity scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Depressive Symptoms
Time Frame: Changes in depressive symptoms scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.
|
Changes in depressive symptoms scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
|
Anxiety
Time Frame: Changes in anxiety scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.
|
Changes in anxiety scores from Baseline (pre-intervention) and after 16 weeks (post-intervention)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY2023-1565
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Physical activity condition
-
University of MinnesotaCompletedPhysical InactivityUnited States
-
Arizona State UniversityCompleted
-
University of North Carolina, GreensboroNational Institute on Aging (NIA); Wake Forest University Health SciencesCompletedHealthy | Physical Activity | Dementia | Alzheimer DiseaseUnited States
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedMultiple SclerosisUnited States
-
University GhentCompletedMental Fatigue | Muscle Fatigue | Event-related PotentialsBelgium
-
The Jerzy Kukuczka Academy of Physical Education...Enrolling by invitationAthletic Performance | Soccer | Isometric Strength TrainingPoland
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
University of PennsylvaniaCompletedNeurocognitive Disorders | Sleep Disorder | Insomnia | Cognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Frontotemporal Dementia | Vascular Dementia | Cognitive Decline | Memory Impairment | Circadian Rhythm Disorders | Hypersomnia | Circadian Rhythm Sleep DisorderUnited States
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Pôle Saint HélierINSA RennesCompletedBrain Injuries | Neurologic Disorder | NeurodegenerationFrance